PTGX vs QGEN
Protagonist Therapeutics, Inc. vs Qiagen N.V. — AI-powered side-by-side comparison
PTGX
Protagonist Therapeutics, Inc.
70
Buy
VS
| Metric | PTGX | QGEN |
|---|
| AI Score |
70
|
71
|
| Price |
$155.12
|
$42.98
|
| P/E Ratio |
127.33×
|
22.03×
|
| ROE |
-21.2%
|
11.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
99.9%
|
61.8%
|
| Debt / Equity |
0.01×
|
0.49×
|
| Dividend Yield |
0.0%
|
6.1%
|
| RSI (14) |
75.9
|
58.7
|
| Beta |
1.794
|
0.62
|
| Expected Upside |
—
|
+1.9%
|
AI Committee View
Current Innellis committee reasoning for PTGX versus QGEN.
QGEN leads by 1 points.
QGEN scores 71/100 (Buy) versus PTGX at 70/100 (Buy).
PTGX Committee View
80% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 76 is in overbought territory — Technical
- Weekly RSI at 87 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 20.7% signals elevated volatility — Risk
QGEN Committee View
75% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.